Bristol Myers Squibb is expected to report fourth-quarter results on February 2, 2026, with Wall Street forecasting revenue growth driven primarily by Opdivo sales. Analysts project mid-single-digit percentage growth in oncology revenues, offsetting a low-double-digit decline in legacy immunology and cardiovascular franchises as key patents expire. Investors will watch sequential trends in research and development spending, which represented 18% of revenue in the third quarter, and margins, after the company delivered a 12.6% net profit margin on $12.22 billion in sales. Management commentary on supply chain costs and the potential timing of new regulatory approvals for oncology pipeline candidates could influence guidance for full-year earnings per share, which street estimates have pegged at approximately $6.74 for 2026.

In the third quarter, Capital Management Corp VA increased its position in Bristol Myers by 9.6%, adding 9,815 shares to reach a total holding of 111,670 shares valued at $5.04 million. Larger institutions also adjusted their allocations: Norges Bank initiated a $1.55 billion position in the second quarter, Charles Schwab Investment Management boosted its stake by 16.8% to 70.8 million shares worth $3.28 billion, and Arrowstreet Capital expanded its exposure by 428.5% to 11.31 million shares. Overall, 76.41% of Bristol Myers shares remain in institutional hands, underscoring broad confidence in the company’s diversified portfolio and cash flow generation.

Consensus among 20 analysts assigns Bristol Myers a Hold rating with a target price of $57.43, reflecting a blend of bullish views on late-stage oncology assets and caution over generic erosion. The stock trades at a trailing P/E of 18.6 and a P/E/G ratio of 0.17, with a beta of 0.29 indicating low market volatility. Technical indicators show a 50-day moving average of $53.41 and a 200-day average of $48.66, while the 52-week trading range spans $42.52 to $63.33. At current levels, the dividend yield stands near 4.6% on an annualized $2.52 payout, supported by a payout ratio of 85.1%. These valuation metrics will be key reference points when management sets guidance for capital allocation and shareholder returns in 2026.